This biotech firm has the first testable vaccine for the novel coronavirus, but the author of today’s article argues that “If you’re looking for massive COVID-19 upside, this stock may not be the best opportunity.” In fact, he recommends selling the stock “pronto” if you purchased it for its vaccine prospects, both in terms of COVID-19 and one of its other major vaccine candidates. Why – and what other “pure COVID-19 play[s]” does he recommend instead? CLICK HERE.